4 citations
,
August 2021 in “Annals of Translational Medicine” In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.
March 2026 in “Journal of Multidisciplinary Applied Natural Science” This study reported that Cosmos caudatus extract alone may therapeutically modulate the AR–FGF-2 axis in a BPH rat model, comparable to finasteride, but combining them disrupted pathway regulation, increasing TGF-β levels.
2 citations
,
January 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that androgen signaling can inhibit Wnt-stimulated growth in prostate basal cell organoids, suggesting a key role in regulating their multipotency.
January 2018 in “Repositorio de Tesis - UNMSM” In this experimental study on Holtzman rats with induced benign prostatic hyperplasia, the researchers observed that the extract of Physalis peruviana (aguaymanto) had a greater therapeutic effect on prostate weight reduction and prostatic epithelium height compared to finasteride and terazosine.
50 citations
,
April 2010 in “Biology direct” This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.
